A fully funded P3 in progress.
Significantly back ended deal.
'Low bar' end points when taking P2 results into account.
ROW rights still up for grabs.
A reputedly superior 'baby brother' drug in the background, now funded through P2 trials for 3 rare diseases.
Realistic chance that the tech could cover the autism spectrum.
IS THIS A DREAM INVESTMENT?
For me, the answer is a big fat NO. Why?
Because the market cap has been destroyed and the register set up to profit an invading cancer intent on a low ball takeover.
A total failure of management.
Ann: Completion of Share Purchase Plan, page-15
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.76 |
Change
0.150(1.10%) |
Mkt cap ! $1.758B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.00 | $13.51 | $5.043M | 365.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3816 | $13.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.78 | 2834 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |